Call Now: +1 858 800 3101 Email: info@innopep.com
Overview | |
---|---|
Description | Programed cell death protein 1 (PD-1) is a cell surface receptor. PD-1 and its ligand PD-L1 are crucial immune checkpoints to downregulate T cell activation, tolerance and immunopathology. Several types of cancer cells overexpress PD-L1 in order to escape from the PD-1/PD-L1 immunosurveillance mechanism. Human PD-L1 inhibitor I is a peptide-based molecule. It binds to human PD-1 and inhibits PD-1/PD-L1 binding. This peptide, PDL-1 inhibitor I has anchor residues, WDY that influence binding of hPD-L1 to hPD-1. Developing inhibitors specifically blocking the PD-1/PD-L1 pathway has become a popular approach toward cancer treatment.PD-L1 Related Peptides:Human PD-L1 inhibitor II, Cat# AS-65582 Human PD-L1 inhibitor III, Cat# AS-65583 Human PD-L1 inhibitor IV, Cat# AS-65584 Human PD-L1 inhibitor V, Cat# AS-65585 |
Sequence | FNWDYSWKSERLKEAYDL |
Sequence (3 Letter) | H - Phe - Asn - Trp - Asp - Tyr - Ser - Trp - Lys - Ser - Glu - Arg - Leu - Lys - Glu - Ala - Tyr - Asp - Leu - OH |
Molecular Weight | 2350.7 |
Properties | |
Purity | % Peak Area By HPLC ≥ 95% |
Storage | -20 °C |
InnoPep Inc. is a company started by a couple of researchers with decades of expertise in peptide synthesis and conjugation aimed at enabling.